Skip to main content

Advertisement

Table 2 Nestin and CD133 expression in human gliomas tissues with different clinical grading

From: Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients

Clinical Grading NO. Nestin (n, %) CD133 (n, %)
   0 1+~2+ 3 0 1+~2+ 3
Low-grade tumors 56 16 (28.6) 32 (57.1) 8(14.3) 20 (37.1) 27 (48.2) 9(16.1)
Astrocytoma 18 7 (38.8) 11 (61.1) 0 (0) 9 (50.0) 9 (50.0) 0 (0)
Ependymoma 15 6 (40.0) 8 (53.3) 1 (6.7) 7 (46.7) 7 (46.7) 1 (6.7)
Oligodendroglioma 11 2 (18.2) 8 (72.7) 1 (9.1) 3 (27.3) 7 (63.6) 1 (9.1)
Oligodendroastrocytoma 4 1 (25.0) 1 (25.0) 2 (50.0) 1 (25.0) 1 (25.0) 2 (50.0)
Pilocytic astrocytoma 8 0 (0) 4 (50.0) 4 (50.0) 0 (0) 3 (37.5) 5 (62.5)
High-grade tumors 69 6(8.7) 36 (52.2) 27 (39.1) 7(10.1) 37 (53.6) 25 (36.2)
GBM 48 4 (8.3) 28 (58.3) 16 (33.3) 5 (10.4) 29 (60.4) 14 (29.2)
Anaplastic astrocytoma 11 2 (18.2) 6 (54.5) 3 (27.3) 2 (18.2) 7 (63.6) 2 (18.2)
Malignant oligodendroglioma 6 0 (0) 1 (16.7) 5 (83.3) 0 (0) 1 (16.7) 5 (83.3)
Malignant ependymoma 4 0 (0) 1 (25.0) 3 (75.0) 0 (0) 0 (0) 4 (100.0)